All Stories

  1. Drug metabolism and antibiotic resistance in micro-organisms
  2. Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach
  3. Characterisation of a putative AraC transcriptional regulator from Mycobacterium smegmatis
  4. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding
  5. Exploration of Piperidinols as Potential Antitubercular Agents
  6. Identification of NAD(P)H Quinone Oxidoreductase Activity in Azoreductases from P. aeruginosa: Azoreductases and NAD(P)H Quinone Oxidoreductases Belong to the Same FMN-Dependent Superfamily of Enzymes
  7. Structure–activity relationships and colorimetric properties of specific probes for the putative cancer biomarker human arylamine N-acetyltransferase 1
  8. Arylamine N‐acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery
  9. From Arylamine N-Acetyltransferase to Folate-Dependent Acetyl CoA Hydrolase: Impact of Folic Acid on the Activity of (HUMAN)NAT1 and Its Homologue (MOUSE)NAT2
  10. Mechanism-based inhibition of HsaD: a C-C bond hydrolase essential for survival ofMycobacterium tuberculosisin macrophage
  11. A Novel Color Change Mechanism for Breast Cancer Biomarker Detection: Naphthoquinones as Specific Ligands of Human Arylamine N-Acetyltransferase 1
  12. Structure of arylamineN-acetyltransferase fromMycobacterium tuberculosisdetermined by cross-seeding with the homologous protein fromM. marinum: triumph over adversity
  13. Design, synthesis and structure–activity relationships of 3,5-diaryl-1H-pyrazoles as inhibitors of arylamine N-acetyltransferase
  14. Piperidinols That Show Anti-Tubercular Activity as Inhibitors of Arylamine N-Acetyltransferase: An Essential Enzyme for Mycobacterial Survival Inside Macrophages
  15. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker
  16. Arylamine N-Acetyltransferases – from Drug Metabolism and Pharmacogenetics to Identification of Novel Targets for Pharmacological Intervention
  17. Communitas
  18. Improvement of the expression and purification of Mycobacterium tuberculosis arylamine N-acetyltransferase (TBNAT) a potential target for novel anti-tubercular agents
  19. Characterization of an oxidoreductase from the arylamine N‐acetyltransferase operon in Mycobacterium smegmatis
  20. Activation of nitrofurazone by azoreductases: multiple activities in one enzyme
  21. Analysis of β-amino alcohols as inhibitors of the potential anti-tubercular target N-acetyltransferase
  22. Novel Small-Molecule Inhibitors of Arylamine N-Acetyltransferases: Drug Discovery by High Throughput Screening
  23. Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases
  24. A Novel Mechanism for Azoreduction
  25. Probing the architecture of the Mycobacterium marinum arylamine N-acetyltransferase active site
  26. Small Molecule Colorimetric Probes for Specific Detection of Human Arylamine N-Acetyltransferase 1, a Potential Breast Cancer Biomarker
  27. Characterisation of CpG methylation in the upstream control region of mouse Nat2: Evidence for a gene–environment interaction in a polymorphic gene implicated in folate metabolism
  28. Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars
  29. Role of tyrosine 131 in the active site of paAzoR1, an azoreductase with specificity for the inflammatory bowel disease prodrug balsalazide
  30. Characterization of a Carbon-Carbon Hydrolase from Mycobacterium tuberculosis Involved in Cholesterol Metabolism
  31. Multiple routes of complement activation by Mycobacterium bovis BCG
  32. Complement activation by Mycobacterium bovis BCG
  33. Inhibition of phago-lysosome fusion and foam cell formation by Mycobacterium bovis BCG induces a Niemann-Pick type C1 like phenotype
  34. Comparison of the Arylamine N-Acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis
  35. Stereoselective synthesis of β-arabino glycosyl sulfones as potential inhibitors of mycobacterial cell wall biosynthesis
  36. ChemInform Abstract: Synthesis of Arabino Glycosyl Triazoles as Potential Inhibitors of Mycobacterial Cell Wall Biosynthesis.
  37. Temperature stability of proteins essential for the intracellular survival of Mycobacterium tuberculosis
  38. Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2
  39. Synthesis of Arabino glycosyl triazoles as potential inhibitors of mycobacterial cell wall biosynthesis
  40. Arylamine N-acetyltransferases: Structural and functional implications of polymorphisms
  41. Update on the pharmacogenetics of NATs: structural considerations
  42. Multiple-routes of complement activation by Mycobacterium bovis BCG
  43. Arylamine N-Acetyltransferases in Mycobacteria
  44. Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1
  45. Changes in consensus arylamine N-acetyltransferase gene nomenclature
  46. Divergence of Cofactor Recognition across Evolution: Coenzyme A Binding in a Prokaryotic Arylamine N-Acetyltransferase
  47. Arylamine N-acetyltransferases: From Structure to Function
  48. Synthesis and anticancer activities of 6-amino amonafide derivatives
  49. Mouse arylamineN-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system
  50. Confirmation of the role of N‐acetyltransferase 2 in teratogen‐induced cleft palate using transgenics and knockouts
  51. Structure of HsaD, a steroid-degrading hydrolase, fromMycobacterium tuberculosis
  52. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism
  53. Molecular Cloning, Characterisation and Ligand-bound Structure of an Azoreductase from Pseudomonas aeruginosa
  54. Arylamine N‐acetyltransferase 1 expression in breast cancer cell lines: A potential marker in estrogen receptor‐positive tumors
  55. Complement interaction with Mycobacterium bovis BCG
  56. Inhibition of mycobacterial arylamine N-acetyltransferase contributes to anti-mycobacterial activity of Warburgia salutaris
  57. ArylamineN-acetyltransferases
  58. Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene
  59. Synthesis of putative chain terminators of mycobacterial arabinan biosynthesis
  60. Kinetic characterisation of arylamine N-acetyltransferase from Pseudomonas aeruginosa
  61. Cloning, functional expression and characterization of Mesorhizobium loti arylamine N‐acetyltransferases: rhizobial symbiosis supplies leguminous plants with the xenobiotic N‐acetylation pathway
  62. Insight into the structure of Mesorhizobium loti arylamine N‐acetyltransferase 2 (MLNAT2): A biochemical and computational study
  63. Characterization of the putative operon containing arylamine N‐acetyltransferase (nat) in Mycobacterium bovis BCG
  64. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines
  65. Structural Analysis of the Genes for Human Arylamine N-Acetyltransferases and Characterisation of Alternative Transcripts
  66. Over-expression, Purification, and Characterization of Recombinant Human Arylamine N-Acetyltransferase 1
  67. Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase
  68. Eukaryotic arylamine N-acetyltransferase
  69. Structure ofMesorhizobium lotiarylamineN-acetyltransferase 1
  70. Pharmacogenomics of Arylamine N-acetyltransferase
  71. Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice
  72. Synthesis and in vitro Evaluation of Novel Small Molecule Inhibitors of Bacterial Arylamine N‐Acetyltransferases (NATs)
  73. Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs)
  74. An approach to identifying novel substrates of bacterial arylamine N -acetyltransferases
  75. NMR investigation of the catalytic mechanism of arylamine N-acetyltransferase from Salmonella typhimurium
  76. Structural investigation of mutant Mycobacterium smegmatis arylamine N-acetyltransferase: a model for a naturally occurring functional polymorphism in Mycobacterium tuberculosis arylamine N-acetyltransferase
  77. Pharmacogenomics of arylamine N-acetyltransferases – from drug metabolism to drug discovery
  78. Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice
  79. The Structure of Arylamine N-acetyltransferase from Mycobacterium smegmatis—An Enzyme which Inactivates the Anti-tubercular Drug, Isoniazid
  80. Expression and Purification of the Rifamycin Amide Synthase, RifF, an Enzyme Homologous to the Prokaryotic Arylamine N-Acetyltransferases
  81. Arylamine N‐Acetyltransferases
  82. The pharmacogenetics of NAT: structural aspects
  83. N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast
  84. Arylamine N-acetyltransferases – of mice, men and microorganisms
  85. Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy
  86. Arylamine N-acetyltransferase (NAT) from Salmonella typhimurium
  87. Update on consensus arylamine N-acetyltransferase gene nomenclature
  88. A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate
  89. Arylamine N-acetyltransferase type 2 (NAT2), chromosome 8 aneuploidy, and identification of a novelNAT1 cosmid clone: An investigation in bladder cancer by interphase FISH
  90. Genes for human arylamine N-acetyltransferases in relation to loss of the short arm of chromosome 8 in bladder cancer
  91. Placental Expression of Arylamine N‐Acetyltransferases: Evidence for Linkage Disequilibrium between NAT1*10 and NAT2*4 Alleles of the Two Human Arylamine N‐Acetyltransferase Loci NAT1 and NAT2
  92. Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimerʼs disease
  93. Purification, Characterization, and Crystallization of anN-HydroxyarylamineO-Acetyltransferase fromSalmonella typhimurium
  94. Genotyping Human Arylamine N-Acetyltransferase Type 1 (NAT1)
  95. Folate and protecting the fetus from environmental toxins
  96. Localization of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice
  97. A fragment consisting of the first 204 amino-terminal amino acids of human arylamine N-acetyltransferase one (NAT1) and the first transacetylation step of catalysis
  98. Arylamine N‐Acetyltransferase in Erythrocytes of Cystic Fibrosis Patients
  99. Arylarnine N-acetyltransferase as a potential biornarker in bladder cancer: fluorescent in situ hybridization and irnmunohistochernistry studies
  100. Xenogenetics in multifactorial disease susceptibility
  101. Enzyme kinetic properties of human recombinant arylamine n-acetyltransferase 2 allotypic variants expressed in Escherichia coli
  102. Nomenclature for N-acetyltransferases
  103. Humoral Factors. The Natural Immune System. Edith Sim
  104. The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4
  105. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants
  106. Arylamine N-acetyltransferase in human red blood cells
  107. Drug metabolising N-acetyltransferase activity in human cell lines
  108. Polymorphism in human N-acetyltransferase — the case of the missing allele
  109. Arylamine N-acetyltransferase from fast (C57BL6) and slow (A/J) N-Acetylating strains of mice
  110. Immunotoxic Side-Effects of Drug Therapy
  111. Immunogenetics and rheumatoid arthritis
  112. Acetohydroxamate, a Urease Inhibitor, Inhibits the Covalent Binding Reaction of Complement Proteins C3 and C4
  113. The generation of active fragments of complement receptor type 2 by trypsin digestion
  114. Hydralazine binds covalently to complement component C4
  115. More drugs interact with the complement system
  116. DRUGS THAT INDUCE SYSTEMIC LUPUS ERYTHEMATOSUS INHIBIT COMPLEMENT COMPONENT C4
  117. Synthesis of tritium‐labelled phosphonium choline
  118. AUTOLYTIC FRAGMENTATION OF COMPLEMENT COMPONENTS C3 AND C4 AND ITS RELATIONSHIP TO COVALENT BINDING ACTIVITY
  119. Membrane Biochemistry
  120. Biological membranes
  121. Introduction
  122. Membrane proteins
  123. Membrane biosynthesis
  124. Membrane lipids
  125. Pattern of degradation of human complement fragment, C3b
  126. The Electron Transport System and Hydrogenase of Paracoccus denitrificans
  127. Comparison of the membrane-bound and detergent-solubilised hydrogenase from Paracoccus denitrificans. Isolation of the hydrogenase
  128. Hydrodynamic Parameters of the Detergent‐Solubilised Hydrogenase from Paracoccus denitrificans
  129. 31P Nuclear magnetic resonance studies of cell membranes labelled with phosphonium phosphatidylcholine